ClinicalTrials.gg
Not yet recruitingNCT07499999BabyTEARSUpdated Mar 30, 2026

Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer

A Phase 2 interventional study of Exemestane and Tamoxifen in Breast Cancer, Ductal Carcinoma and Estrogen-receptor-positive Breast Cancer, sponsored by Dana-Farber Cancer Institute. Not yet recruiting at 2 sites in United States. Open to female participants. Per ClinicalTrials.gov, last updated 2026-03-30.

Sponsored by Dana-Farber Cancer Institute · Phase 2, Interventional, and Prevention

How we know · 4 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
140
Allocation
Randomized
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 103 studies testing exemestane in Breast Neoplasms — 20 open to participants now, 26 under way, 7 of them phase 3. exemestane · Breast Neoplasms.

Planned enrollment
47th of 101
140 · median 123
Started
2026
with 3 others
Phase 2
50 of 103
14 open now
Primary completion
2027-08
later than 10 of 25 live
Registered
102nd of 103
by date
Lead sponsor
2 of 103
Dana-Farber Cancer Institute

Among the 103 studies testing exemestane in Breast Neoplasms, this one is the 47th largest by planned enrollment of the 101 interventional ones that give a count, is one of 4 that started in 2026, is one of 50 in phase 2, reaches primary completion later than 10 of the 25 other live ones, and was the 102nd registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

20 of the 103 studies testing exemestane in Breast Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 20 open studies →

About exemestane

exemestane: first FDA approval 1999 (AROMASIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 103 studies testing exemestane in Breast Neoplasms, or all of them as a file.
02

Study summary

The goal of this research study is to evaluate the efficacy and safety of low-dose exemestane versus low-dose tamoxifen in post-menopausal women at high risk for breast cancer.

The names of the study drugs involved in this study are:

  • Exemestane (a type of steroidal aromatase inhibitor)
  • Tamoxifen (a type of selective estrogen receptor modulator)
Read the detailed description

This randomized, double-blind, phase II trial is to evaluate the efficacy and safety of low-dose "baby" exemestane versus low-dose "baby" tamoxifen in post-menopausal women at high risk for breast cancer. Both medications are used at full doses for breast cancer treatment and to reduce breast cancer risk. Low dose tamoxifen has been shown to be effective at reducing risk with better tolerance.

Participants will be randomized into one of two study groups: Group A: Exemestane versus Group B: Tamoxifen. Randomization means a participant is placed into a study group by chance. Neither a participant or the research doctor will choose or know what group a participant is placed in. This is called a "double-blind".

The U.S. Food and Drug Administration (FDA) has not approved tamoxifen or exemestane for ER+ DCIS, High Risk Lesions, or being at high-risk for breast cancer but it has been approved for other uses.

The research study procedures include screening for eligibility, in-clinic visits, questionnaires, blood tests, Mammography scans, and bone density (DEXA) scans.

Participation in this research study is expected to last about 12 months. It is expected that about 140 people will take part in this research study. The Breast Cancer Research Foundation is supporting this research study by providing funding. MRIGlobal is providing support by supplying the study drugs.

03

Conditions studied

  • Breast Cancer
  • Ductal Carcinoma
  • Estrogen-receptor-positive Breast Cancer
  • Atypical Lobular Hyperplasia
  • BRCA2 Mutation
  • CHEK2 Gene Mutation
  • Ataxia Telangiectasia Mutated Gene Mutation

Keywords

  • Breast Cancer
  • High Risk Breast Cancer
  • Cancer Prevention
  • Ductual Carcinoma in Site
  • Estrogen Receptor Positive
  • High Risk Lesions
  • HRL
  • Atypical Lobular Hyperplasia
  • BRCA2
  • CHEK2
  • ATM
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • state is defined⁸ as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal or hormonal replacement therapy.
  • Any of the following criteria must be met:

    • Recent (within 12 months from date of consent form signature) histologic diagnosis of ER+ve (>5%) DCIS (patients with DCIS should have undergone breast-conserving therapy i.e. lumpectomy to remove the tumor with negative surgical margins followed by radiotherapy (see footnote 1 below)) diagnosis within 3 years of HRL (ADH, LCIS, ALH), or;
    • At least 3% breast cancer risk at 5 years (or 5% risk at 10yrs) per one of the following risk models: the Breast Cancer Surveillance Consortium risk calculator V3 or Tyrer-Cuzick model V8 or;
    • Known carriers of a germline pathogenic/likely pathogenetic variant in the following moderate penetrance genes (CHEK2 or ATM), or women with chest wall irradiation before age of 30 years
  • - Performance Status (ECOG-PS) 0-1
  • Able to swallow oral medications
  • Participants with a prior or concurrent whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the regimen are eligible for this trial. Specifically, all cancers diagnosed since 3 years or longer except for breast and endometrial are eligible.
  • Ability to understand and the willingness to sign a written document
  • Mammography performed up to 6 months before the trial consent form signature
  • DEXA performed up to 12 months before the trial consent form signature
  • ≥ 10 years
  • Normal liver function tests and blood cell count
  • Negative gynecological examination performed up to 6 months before the trial consent form signature.

ᶥ While DCIS and ADH are routinely excised, and treatment of DCIS often includes radiotherapy, lobular neoplasia (ALH and classic LCIS) are not routinely excised in most US centers unless radiologic-pathologic findings are discordant given the very low risk of an associated cancer.11,12 Participants with DCIS should have undergone breast-conserving therapy i.e. lumpectomy to remove the tumor with negative surgical margins followed by radiotherapy. All DCIS will require excision to clear margins per the SSO/ASCO/ASTRO margin guidelines for DCIS.88 In selected cases, the decision to omit RT might be taken according to low risk clinical-pathological factors (e.g., age>70, low grade, size \< 1 cm, and genomic assays if available) as well as patient preference after full discussion of the risks and benefits.

Exclusion Criteria:

  • Pre/perimenopausal women: exemestane is only effective in post-menopausal women
  • History of DVT or PE: tamoxifen can increase tendency to blood clot
  • Endometrial cancer: full-dose tamoxifen is associated with increased risk of endometrial cancers
  • Macular disorders: tamoxifen is associated with retinal damage
  • Inability to comply with study procedures: standard
  • Prior use of antiestrogens within 12 months from the date of the trial consent form signature: there can be long duration effects from antiestrogens that could influence trial drug effects
  • Use of hormone replacement therapy (HRT) within 3 months from the date of the trial consent form signature: similarly, wish to avoid any long lasting effect before alternate effect from study drugs
  • Severe osteoporosis (T score ≤ 2.5 at either spine or hip), or recent vertebral fracture (within 6 months) not treated with zoledronic acid or denosumab: Exemestane is an aromatase inhibitor which can worsen bone loss (osteoporosis)
  • Current use of terbinafine, quinidine, cinacalcet, rifampicin, phenytoin, carbamazepine, phenobarbital, St. John's wort, warfarin, erythromycin, cyclosporin, nifedipine and any concomitant coumarin-type anti-coagulant therapy: these drugs compete for the Cytochrome P450 metabolic pathways of tamoxifen and exemestane
  • Moderate or severe renal impairment: Exemestane is eliminated equally by liver and renal metabolism
  • Known to study drugs: standard

Screening Eligibility Criteria

To register a participant to the screening phase, the following documents should be provided by the participating site:

Signed participant consent form

  • Postmenopausal status, and any of the following:

    • Histological report of ER-positive DCIS within 12 months, or HRL of the breast within 3 years from date of consent form signature, or;
    • Report of risk assessment ≥3% in 5 years or 5% in 10 years of breast cancer according to the selected risk model(s) different criteria within 6 months from screening, or;
    • Documentation of women carriers of a germline pathogenic/likely pathogenetic variant in a moderate penetrance gene (CHEK2 or ATM), or;
    • Documented history of chest wall radiotherapy before age 30.
  • Inclusion of Women and Minorities

Only women will be recruited in the study given that breast cancer is much more frequent in women than men and because exemestane is in men because of risk of uncontrolled gonadal stimulation. Women of all races and ethnic groups are eligible for this trial. At participating sites, efforts will be made to enroll women from diverse ethnic and socio-economic backgrounds, including recruitment of non-white women in a selected New York city area.

NIH policy requires that women and members of minority groups and their subpopulations be included in all NIH-supported biomedical and behavioral research projects involving NIH-defined clinical research unless a clear and compelling rationale and justification establishes to the satisfaction of the funding Institute \& Center (IC) Director that inclusion is inappropriate with respect to the health of the subjects or the purpose of the research. Exclusion under other circumstances designated by the Director, NIH, upon the recommendation of an IC Director based on a compelling rationale and justification. Cost is not an acceptable reason for exclusion except when the study would duplicate data from other sources. Women of should not be routinely excluded from participation in clinical research.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    Low-Dose Exemestane

    Participants will be randomized 1:1 with a permuted-block technique and stratified by center and will complete: * Baseline visit with assessments * Predetermined dose of Exemestane 1x on every odd day for 12 months * 3 month in-clinic visit * 6 month in-clinic visit * 9 month in-clinic visit * 12 month end of intervention in-clinic visit * Follow up for 12 months

    Drug: Exemestane

  • Experimental
    Low-Dose Tamoxifen

    Participants will be randomized 1:1 with a permuted-block technique and stratified by center and will complete: * Baseline visit with assessments * Predetermined dose of Tamoxifen 1x on every odd day for 12 months * 3 month in-clinic visit * 6 month in-clinic visit * 9 month in-clinic visit * 12 month end of intervention in-clinic visit * Follow up for 12 months

    Drug: Tamoxifen

Interventions

  • A steroidal aromatase inhibitor, blinded capsules taken orally, per protocol.

    Also known as: C20H24O2

  • A selective estrogen receptor modulator, blinded capsules taken orally, per protocol.

    Also known as: C32H37NO8

06

What researchers measure

Primary outcomes

  1. Difference in Overall Domain Score Change From Baseline in Menopause-Specific Quality of Life Questionnaire (MENQOL) Between the Two Arms at 12 Months

    The MENQOL assesses the degree to which menopausal symptoms are troublesome in four domains: vasomotor (three items), sexual (three items), physical (seven items), and psychosocial (16 items). Each item is answered with Yes or No. If the response is Yes, the participant rates how bothersome the symptom was on a scale from 0 to 6, where 0 indicates "not at all bothered" and 6 indicates "extremely bothered." For each participant, the difference between the baseline and 12-month overall MENQOL score will be calculated and defined as the "change."

    Time frame: 12 Months

Secondary outcomes

  1. Difference of Free Estradiol Levels between Two Arms at 12 Months

    Free estradiol concentration in blood will be measured to compare the hormonal effects of babyexe versus babytam.

    Time frame: 12 Months

  2. Difference of Estradiol/Sex Hormone Binding Globulin (SHBG) Levels between Two Arms at 12 Months

    The estradiol/SHBG ratio will be calculated as total estradiol divided by SHBG to evaluate differences in hormonal effects between babyexe and babytam.

    Time frame: 12 Months

  3. Difference of Insulin-like Growth Factor Binding Protein 3 (IGFBP-3) Levels Between Two Arms at 12 Months

    Blood levels of IGF-I will be measured to compare the effects of babyexe and babytam on IGF-I.

    Time frame: 12 Months

  4. Insulin-like Growth Factor I (IGF-I)/Insulin-like Growth Factor Binding Protein 3 (IGFBP-3) Ratio Between Two Arms at 12 Months

    The ratio of IGF-I to IGFBP-3 in blood will be calculated to compare the effects of babyexe and babytam on IGF system balance.

    Time frame: 12 Months

  5. Overall Domain Score Change From Baseline in Menopause-Specific Quality of Life Questionnaire (MENQOL) at 6 Months

    The MENQOL assesses the degree to which menopausal symptoms are troublesome in four domains: vasomotor (three items), sexual (three items), physical (seven items), and psychosocial (16 items). Each item is answered with Yes or No. If the response is Yes, the participant rates how bothersome the symptom was on a scale from 0 to 6, where 0 indicates "not at all bothered" and 6 indicates "extremely bothered." For each participant, the difference between the baseline and 6-month overall MENQOL score will be calculated and defined as the "change."

    Time frame: 6 months

  6. Free Estradiol Levels

    Free estradiol concentration in blood will be measured to compare the hormonal effects of babyexe versus babytam.

    Time frame: 6 Months

  7. Estradiol/Sex Hormone Binding Globulin (SHBG) Levels

    The estradiol/SHBG ratio will be calculated as total estradiol divided by SHBG to evaluate differences in hormonal effects between babyexe and babytam.

    Time frame: 6 months

  8. Insulin-like Growth Factor I (IGF-I) Levels

    Blood levels of IGF-I will be measured to compare the effects of babyexe and babytam on IGF-I.

    Time frame: 6 months

  9. Insulin-like Growth Factor Binding Protein 3 (IGFBP-3) Levels

    Blood levels of IGFBP-3 will be measured to compare the effects of babyexe and babytam on IGFBP-3.

    Time frame: 6 months

  10. Insulin-like Growth Factor I (IGF-I)/Insulin-like Growth Factor Binding Protein 3 (IGFBP-3) Ratio

    The ratio of IGF-I to IGFBP-3 in blood will be calculated to compare the effects of babyexe and babytam on IGF system balance.

    Time frame: 6 months

  11. Physical Domain Score Change From Baseline in Menopause-Specific Quality of Life Questionnaire (MENQOL) Between the Two Arms at 6 Months and 12 months

    The MENQOL physical domain, which includes seven items, assesses the degree to which physical menopausal symptoms are troublesome. Each item is answered with Yes or No. If the response is Yes, the participant rates how bothersome the symptom was on a scale from 0 ("not at all bothered") to 6 ("extremely bothered"). For each participant, the difference between the baseline and 6-month physical domain MENQOL score will be calculated and defined as the "change."

    Time frame: 6 months and 12 months

  12. Sexual Domain Score Change From Baseline in Menopause-Specific Quality of Life Questionnaire (MENQOL)

    The MENQOL sexual domain, which includes three items, assesses the degree to which sexual menopausal symptoms are troublesome. Each item is answered with Yes or No. If the response is Yes, the participant rates how bothersome the symptom was on a scale from 0 ("not at all bothered") to 6 ("extremely bothered"). For each participant, the difference between the baseline and 6-month sexual domain MENQOL score will be calculated and defined as the "change."

    Time frame: 6 months and 12 months

  13. Psychosocial Domain Score Change From Baseline in Menopause-Specific Quality of Life Questionnaire (MENQOL)

    The MENQOL psychosocial domain, which includes sixteen items, assesses the degree to which psychosocial menopausal symptoms are troublesome. Each item is answered with Yes or No. If the response is Yes, the participant rates how bothersome the symptom was on a scale from 0 ("not at all bothered") to 6 ("extremely bothered"). For each participant, the difference between the baseline and 6-month psychosocial domain MENQOL score will be calculated and defined as the "change."

    Time frame: 6 months and 12 months

  14. Vasomotor Domain Score Change From Baseline in Menopause-Specific Quality of Life Questionnaire (MENQOL)

    The MENQOL vasomotor domain, which includes three items, assesses the degree to which vasomotor menopausal symptoms are troublesome. Each item is answered with Yes or No. If the response is Yes, the participant rates how bothersome the symptom was on a scale from 0 ("not at all bothered") to 6 ("extremely bothered"). For each participant, the difference between the baseline and 6-month vasomotor domain MENQOL score will be calculated and defined as the "change."

    Time frame: 6 months and 12 months

  15. Global Adverse Event (AE) Rate

    Global AE rate is defined as the proportion of participants who experience any AE. AE is summarized and graded based on CTCAE v 5.0.

    Time frame: 12 Months

  16. Grade 2 or Higher Adverse Event (AE) Rate

    Grade 2 or higher AE rate is defined as the proportion of participants who experience grade 2 or higher AE. AE is summarized and graded based on CTCAE v 5.0.

    Time frame: 12 months

  17. Grade 3 or Higher Adverse Event (AE) Rate

    Grade 3 or higher AE rate is defined as the proportion of participants who experience grade 2 or higher AE. AE is summarized and graded based on CTCAE v 5.0.

    Time frame: 12 months

  18. Distribution of Maximum Adverse Event Grade per Participant

    The maximum adverse event (AE) grade experienced by each participant during the treatment period will be summarized to characterize the overall toxicity profile. Adverse events will be graded according to the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. For each participant, the highest AE grade observed at any time during the treatment period will be identified, and the distribution of these maximum grades across participants will be reported, in accordance with the statistical considerations for toxicity evaluation described in Section 16.15 of the protocol.

    Time frame: 12 months

  19. Medication Adherence Assessed by PMAS

    Medication adherence will be assessed using the PMAS instrument, as specified in Appendix H of the protocol. PMAS is a validated wording-based adherence scale and does not generate a continuous numeric summary score. Therefore, adherence will be operationalized categorically, consistent with its original validation methodology. Participants will be classified into predefined adherence categories based on their item responses (e.g., high adherence versus non-high adherence). Adherence will be summarized as the proportion of participants meeting the definition of "high adherence" within each treatment arm. Between-arm comparisons will be based on categorical distributions rather than mean or continuous scores, in accordance with Sections 9.10-9.11 of the protocol.

    Time frame: 6 months and 12 months

  20. BPI (Brief Pain Inventory) Score Change from Baseline

    Pain will be assessed using BPI, a validated questionnaire that measures both pain intensity and the degree to which pain interferes with daily activities. Each item is scored from 0 to 10, with higher scores indicating worse pain or greater interference.

    Time frame: 6 months and 12 months

  21. C-Telopeptide Levels

    Blood levels of C-telopeptide, a marker of bone resorption, will be measured assess changes in bone turnover.

    Time frame: 6 months and 12 months

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: Yes — The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data can be shared no earlier than 1 year following the date of publication

Access criteria: DFCI- Contact the Belfer office for Dana -Farber Innovations (BODFI) at innovations@dfci.harvard.edu

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Aug 2027, 11 months later.

Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's planned 11 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2026
First posted
Mar 30, 2026
StartEst.
Sep 9, 2026
Primary completionEst.
Aug 31, 2027
CompletionEst.
Aug 31, 2028
Last update
Mar 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07499999
Collaborators
Breast Cancer Research Foundation
Responsible party
Judy E. Garber, MD (Principal Investigator, Dana-Farber Cancer Institute) — Principal investigator
First posted
Mar 30, 2026
Start date
Sep 9, 2026 (estimated)
Primary completion
Aug 31, 2027 (estimated)
Completion
Aug 31, 2028 (estimated)
Last update
Mar 30, 2026

Study contacts

Judy Garber, MD, MPH
Contact
judy_garber@dfciharvard.edu
617-632-2282
Judy Garber, MD. MPH
Contact
judy_garber@dfciharvard.edu
617-582-8321
Judy Garber, MD. MPH
principal investigator · Dana-Farber Cancer Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Exemestane · Tamoxifen

Start the discussion